PPARG and fatty liver disease: The results showed that mimic treatment targeted PPARγ to induce inflammation and hepatic steatosis in epididymal white adipose tissue (eWAT), both of which are known to participate in glucose intolerance and dyslipidemia, and the effects of mimic treatment could be reverted by the lipolysis inhibitor acipimox or the PPARα agonist fenofibrate (Castaño et al., 2018).